General
Levothyroxine has a narrow therapeutic index. Regardless of the
indication for use, careful dosage titration is necessary to avoid the
consequences of over- or under-treatment. These consequences include, among
others, effects on growth and development, cardiovascular function, bone
metabolism, reproductive function, cognitive function, emotional state,
gastrointestinal function, and on glucose and lipid metabolism. Many drugs
interact with levothyroxine sodium necessitating adjustments in dosing to
maintain therapeutic response (see PRECAUTIONS:
Drug Interactions).
Effects on Bone Mineral Density
In women, long-term levothyroxine sodium therapy has been
associated with increased bone resorption, thereby decreasing bone mineral
density, especially in postmenopausal women on greater than replacement doses or
in women who are receiving suppressive doses of levothyroxine sodium. The
increased bone resorption may be associated with increased serum levels and
urinary excretion of calcium and phosphorous, elevations in bone alkaline
phosphatase and suppressed serum parathyroid hormone levels. Therefore, it is
recommended that patients receiving levothyroxine sodium be given the minimum
dose necessary to achieve the desired clinical and biochemical response.
Patients with Underlying Cardiovascular Disease
Exercise caution when administering levothyroxine to patients
with cardiovascular disorders and to the elderly in whom there is an increased
risk of occult cardiac disease. In these patients, levothyroxine therapy should
be initiated at lower doses than those recommended in younger individuals or in
patients without cardiac disease (see WARNINGS; PRECAUTIONS:
Geriatric Use; and DOSAGE AND
ADMINISTRATION). If cardiac symptoms develop or worsen, the levothyroxine
dose should be reduced or withheld for one week and then cautiously restarted at
a lower dose. Overtreatment with levothyroxine sodium may have adverse
cardiovascular effects such as an increase in heart rate, cardiac wall
thickness, and cardiac contractility and may precipitate angina or arrhythmias.
Patients with coronary artery disease who are receiving levothyroxine therapy
should be monitored closely during surgical procedures, since the possibility of
precipitating cardiac arrhythmias may be greater in those treated with
levothyroxine. Concomitant administration of levothyroxine and sympathomimetic
agents to patients with coronary artery disease may precipitate coronary
insufficiency.
Patients with Nontoxic Diffuse Goiter or Nodular
Thyroid Disease
Exercise caution when administering levothyroxine to patients
with nontoxic diffuse goiter or nodular thyroid disease in order to prevent
precipitation of thyrotoxicosis (see WARNINGS). If the serum TSH is already
suppressed, levothyroxine sodium should not be administered (see
CONTRAINDICATIONS).
Associated Endocrine DisordersHypothalamic/Pituitary Hormone Deficiencies
In patients with secondary or tertiary hypothyroidism, additional
hypothalamic/pituitary hormone deficiencies should be considered, and, if
diagnosed, treated (see PRECAUTIONS:
Autoimmune Polyglandular Syndrome for adrenal insufficiency).
Autoimmune Polyglandular Syndrome
Occasionally, chronic autoimmune thyroiditis may occur in
association with other autoimmune disorders such as adrenal insufficiency,
pernicious anemia, and insulin-dependent diabetes mellitus. Patients with
concomitant adrenal insufficiency should be treated with replacement
glucocorticoids prior to initiation of treatment with levothyroxine sodium.
Failure to do so may precipitate an acute adrenal crisis when thyroid hormone
therapy is initiated, due to increased metabolic clearance of glucocorticoids by
thyroid hormone. Patients with diabetes mellitus may require upward adjustments
of their antidiabetic therapeutic regimens when treated with levothyroxine (see
PRECAUTIONS:
Drug Interactions).
Other Associated Medical Conditions
Infants with congenital hypothyroidism appear to be at increased
risk for other congenital anomalies, with cardiovascular anomalies (pulmonary
stenosis, atrial septal defect, and ventricular septal defect) being the most
common association.
Information for Patients
Patients should be informed of the following information to aid
in the safe and effective use of levothyroxine sodium:
- Notify your physician if you are allergic to any foods or medicines, are
pregnant or intend to become pregnant, are breast-feeding or are taking any
other medications, including prescription and over-the-counter
preparations.
- Notify your physician of any other medical conditions you may have,
particularly heart disease, diabetes, clotting disorders, and adrenal or
pituitary gland problems. Your dose of medications used to control these other
conditions may need to be adjusted while you are taking levothyroxine sodium. If
you have diabetes, monitor your blood and/or urinary glucose levels as directed
by your physician and immediately report any changes to your physician. If you
are taking anticoagulants (blood thinners), your clotting status should be
checked frequently.
- Use levothyroxine sodium only as prescribed by your physician. Do not
discontinue or change the amount you take or how often you take it, unless
directed to do so by your physician.
- The levothyroxine in levothyroxine sodium tablets is intended to replace a
hormone that is normally produced by your thyroid gland. Generally, replacement
therapy is to be taken for life, except in cases of transient hypothyroidism,
which is usually associated with an inflammation of the thyroid gland
(thyroiditis).
- Take levothyroxine sodium in the morning on an empty stomach, at least
one-half hour before eating any food.
- It may take several weeks before you notice an improvement in your
symptoms.
- Notify your physician if you experience any of the following symptoms: rapid
or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache,
nervousness, irritability, sleeplessness, tremors, change in appetite, weight
gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever,
changes in menstrual periods, hives or skin rash, or any other unusual medical
event.
- Notify your physician if you become pregnant while taking levothyroxine
sodium. It is likely that your dose of levothyroxine sodium will need to be
increased while you are pregnant.
- Notify your physician or dentist that you are taking levothyroxine sodium
prior to any surgery.
- Partial hair loss may occur rarely during the first few months of
levothyroxine sodium therapy, but this is usually temporary.
- Levothyroxine sodium should not be used as a primary or adjunctive therapy
in a weight control program.
- Keep levothyroxine sodium tablets out of the reach of children. Store
levothyroxine sodium tablets away from heat, moisture, and light.
- Agents such as iron and calcium supplements and antacids can decrease the
absorption of levothyroxine sodium tablets. Therefore, levothyroxine sodium
tablets should not be administered within 4 hours of these agents.
Laboratory TestsGeneral
The diagnosis of hypothyroidism is confirmed by measuring TSH
levels using a sensitive assay (second generation assay sensitivity < 0.1 mIU/L
or third generation assay sensitivity < 0.01 mIU/L) and measurement of
free-T4.
The adequacy of therapy is determined by periodic assessment of appropriate
laboratory tests and clinical evaluation. The choice of laboratory tests depends
on various factors including the etiology of the underlying thyroid disease, the
presence of concomitant medical conditions, including pregnancy, and the use of
concomitant medications (see PRECAUTIONS:
Drug Interactions and Drug-Laboratory
Test Interactions). Persistent clinical and laboratory evidence of
hypothyroidism despite an apparent adequate replacement dose of levothyroxine
sodium may be evidence of inadequate absorption, poor compliance, drug
interactions, or decreased T4 potency of the drug
product.
Adults
In adult patients with primary (thyroidal) hypothyroidism, serum
TSH levels (using a sensitive assay) alone may be used to monitor therapy. The
frequency of TSH monitoring during levothyroxine dose titration depends on the
clinical situation but it is generally recommended at 6 to 8 week intervals
until normalization. For patients who have recently initiated levothyroxine
therapy and whose serum TSH has normalized or in patients who have had their
dosage or brand of levothyroxine changed, the serum TSH concentration should be
measured after 8 to 12 weeks. When the optimum replacement dose has been
attained, clinical (physical examination) and biochemical monitoring may be
performed every 6 to 12 months, depending on the clinical situation, and
whenever there is a change in the patient’s status. It is recommended that a
physical examination and a serum TSH measurement be performed at least annually
in patients receiving levothyroxine sodium (see WARNINGS, PRECAUTIONS,
and DOSAGE
AND ADMINISTRATION).
Pediatrics
In patients with congenital hypothyroidism, the adequacy of
replacement therapy should be assessed by measuring both serum TSH (using a
sensitive assay) and total- or free-T4. During the first
3 years of life, the serum total- or free-T4 should be
maintained at all times in the upper half of the normal range. While the aim of
therapy is to also normalize the serum TSH level, this is not always possible in
a small percentage of patients, particularly in the first few months of therapy.
TSH may not normalize due to a resetting of the pituitary-thyroid feedback
threshold as a result of in utero hypothyroidism.
Failure of the serum T4 to increase into the upper half
of the normal range within 2 weeks of initiation of levothyroxine sodium therapy
and/or of the serum TSH to decrease below 20 mU/L within 4 weeks should alert
the physician to the possibility that the child is not receiving adequate
therapy. Careful inquiry should then be made regarding compliance, dose of
medication administered, and method of administration prior to raising the dose
of levothyroxine sodium.
The recommended frequency of monitoring of TSH and total or free T4 in children is as follows: at 2 and 4 weeks after the
initiation of treatment; every 1 to 2 months during the first year of life;
every 2 to 3 months between 1 and 3 years of age; and every 3 to 12 months
thereafter until growth is completed. More frequent intervals of monitoring may
be necessary if poor compliance is suspected or abnormal values are obtained. It
is recommended that TSH and T4 levels, and a physical
examination, if indicated, be performed 2 weeks after any change in
levothyroxine sodium dosage. Routine clinical examination, including assessment
of mental and physical growth and development, and bone maturation, should be
performed at regular intervals (see PRECAUTIONS:
Pediatric Use and DOSAGE AND
ADMINISTRATION).
Secondary (Pituitary) and Tertiary (Hypothalamic)
Hypothyroidism
Adequacy of therapy should be assessed by measuring serum
free-T4 levels, which should be maintained in the upper
half of the normal range in these patients.
Drug Interactions
Many drugs affect thyroid hormone pharmacokinetics and metabolism
(e.g., absorption, synthesis, secretion, catabolism, protein binding, and target
tissue response) and may alter the therapeutic response to levothyroxine sodium.
In addition, thyroid hormones and thyroid status have varied effects on the
pharmacokinetics and actions of other drugs. A listing of drug-thyroidal axis
interactions is contained in Table 2.
The list of drug-thyroidal axis interactions in Table 2 may not be
comprehensive due to the introduction of new drugs that interact with the
thyroidal axis or the discovery of previously unknown interactions. The
prescriber should be aware of this fact and should consult appropriate reference
sources (e.g., package inserts of newly approved drugs, medical literature) for
additional information if a drug-drug interaction with levothyroxine is
suspected.
Table 2: Drug-Thyroidal Axis Interactions| Drug or
Drug Class | Effect |
| Drugs that
may reduce TSH secretion - the reduction is not sustained; therefore,
hypothyroidism does not occur |
Dopamine/Dopamine
Agonists Glucocorticoids Octreotide | Use of these agents may result in a
transient reduction in TSH secretion when administered at the following doses:
Dopamine (>1 mcg/kg/min); Glucocorticoids (hydrocortisone > 100 mg/day or
equivalent); Octreotide (> 100 mcg/day). |
| Drugs that
alter thyroid hormone secretion |
| Drugs that
may decrease thyroid hormone secretion, which may result in
hypothyroidism |
Aminoglutethimide Amiodarone Iodide (including
iodine-containing radiographic contrast
agents) Lithium Methimazole Propylthiouracil
(PTU) Sulfonamides Tolbutamide | Long-term lithium therapy can result in
goiter in up to 50% of patients, and either subclinical or overt hypothyroidism,
each in up to 20% of patients. The fetus, neonate, elderly and euthyroid
patients with underlying thyroid disease (e.g., Hashimoto’s thyroiditis or with
Grave’s disease previously treated with radioiodine or surgery) are among those
individuals who are particularly susceptible to iodine-induced hypothyroidism.
Oral cholecystographic agents and amiodarone are slowly excreted, producing more
prolonged hypothyroidism than parenterally administered iodinated contrast
agents. Long-term aminoglutethimide therapy may minimally decrease T4 and T3 levels and increase TSH,
although all values remain within normal limits in most patients. |
| Drugs that
may increase thyroid hormone secretion, which may result in
hyperthyroidism |
Amiodarone Iodide (including iodine-containing radiographic
contrast agents) | Iodide and drugs that contain
pharmacologic amounts of iodide may cause hyperthyroidism in euthyroid patients
with Grave’s disease previously treated with antithyroid drugs or in euthyroid
patients with thyroid autonomy (e.g., multinodular goiter or hyperfunctioning
thyroid adenoma). Hyperthyroidism may develop over several weeks and may persist
for several months after therapy discontinuation. Amiodarone may induce
hyperthyroidism by causing thyroiditis. |
| Drugs that
may decrease T4 absorption, which may result in
hypothyroidism |
Antacids - Aluminum & Magnesium Hydroxides -
Simethicone Bile Acid Sequestrants - Cholestyramine -
Colestipol Calcium Carbonate Cation Exchange Resins -
Kayexalate Ferrous Sulfate Orlistat Sucralfate | Concurrent use may reduce the efficacy
of levothyroxine by binding and delaying or preventing absorption, potentially
resulting in hypothyroidism. Calcium carbonate may form an insoluble chelate
with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex.
Administer levothyroxine at least 4 hours apart from these agents. Patients
treated concomitantly with orlistat and levothyroxine sodium should be monitored
for changes in thyroid function. |
| Drugs that
may alter T4 and T3 serum
transport - but FT4 concentration remains normal; and
therefore, the patient remains euthyroid |
| Drugs that may
increase serum TBG concentration | Drugs that may
decrease serum TBG concentration |
Clofibrate Estrogen-containing oral
contraceptives Estrogens
(oral) Heroin/Methadone 5-Fluorouracil Mitotane Tamoxifen | Androgens/Anabolic
Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic
Acid |
| Drugs that
may cause protein-binding site displacement |
Furosemide (> 80 mg
IV) Heparin Hydantoins Non-Steroidal Anti-Inflammatory Drugs -
Fenamates - Phenylbutazone Salicylates (> 2 g/day) | Administration of these agents with
levothyroxine results in an initial transient increase in FT4 . Continued administration results in a decrease in serum
T4 and normal FT4 and TSH
concentrations and, therefore, patients are clinically euthyroid. Salicylates
inhibit binding of T4 and T3 to
TBG and transthyretin. An initial increase in serum FT4
is followed by return of FT4 to normal levels with
sustained therapeutic serum salicylate concentrations, although total-T4 levels may decrease by as much as 30%. |
| Drugs that
may alter T4 and T3
metabolism |
| Drugs that
may increase hepatic metabolism, which may result in
hypothyroidism |
Carbamazepine Hydantoins Phenobarbital Rifampin | Stimulation of hepatic microsomal
drug-metabolizing enzyme activity may cause increased hepatic degradation of
levothyroxine, resulting in increased levothyroxine requirements. Phenytoin and
carbamazepine reduce serum protein binding of levothyroxine, and total- and
free-T4 may be reduced by 20% to 40%, but most patients
have normal serum TSH levels and are clinically euthyroid. |
| Drugs that
may decrease T4 5'-deiodinase activity |
Amiodarone Beta-adrenergic antagonists - (e.g., Propranolol
> 160 mg/day) Glucocorticoids - (e.g., Dexamethasone ³ 4
mg/day) Propylthiouracil (PTU) | Administration of these enzyme
inhibitors decreases the peripheral conversion of T4 to
T3, leading to decreased T3
levels. However, serum T4 levels are usually normal but
may occasionally be slightly increased. In patients treated with large doses of
propranolol (>160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and
patients are clinically euthyroid. It should be noted that actions of particular
beta-adrenergic antagonists may be impaired when the hypothyroid patient is
converted to the euthyroid state. Short-term administration of large doses of
glucocorticoids may decrease serum T3 concentrations by
30% with minimal change in serum T4 levels. However,
long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG
production (see above). |
| Miscellaneous |
Anticoagulants (oral) - Coumarin Derivatives - Indandione
Derivatives | Thyroid hormones appear to increase the
catabolism of vitamin K-dependent clotting factors, thereby increasing the
anticoagulant activity of oral anticoagulants. Concomitant use of these agents
impairs the compensatory increases in clotting factor synthesis. Prothrombin
time should be carefully monitored in patients taking levothyroxine and oral
anticoagulants and the dose of anticoagulant therapy adjusted
accordingly. |
Antidepressants - Tricyclics (e.g., Amitriptyline) -
Tetracyclics (e.g., Maprotiline) - Selective Serotonin Reuptake Inhibitors
(SSRIs; e.g., Sertraline) | Concurrent use of tri/tetracyclic
antidepressants and levothyroxine may increase the therapeutic and toxic effects
of both drugs, possibly due to increased receptor sensitivity to catecholamines.
Toxic effects may include increased risk of cardiac arrhythmias and CNS
stimulation; onset of action of tricyclics may be accelerated. Administration of
sertraline in patients stabilized on levothyroxine may result in increased
levothyroxine requirements. |
Antidiabetic Agents - Biguanides - Meglitinides -
Sulfonylureas - Thiazolidinediones - Insulin | Addition of levothyroxine to
antidiabetic or insulin therapy may result in increased antidiabetic agent or
insulin requirements. Careful monitoring of diabetic control is recommended,
especially when thyroid therapy is started, changed, or discontinued. |
| Cardiac Glycosides | Serum digitalis glycoside levels may be
reduced in hyperthyroidism or when the hypothyroid patient is converted to the
euthyroid state. Therapeutic effect of digitalis glycosides may be
reduced. |
Cytokines - Interferon-α - Interleukin-2 | Therapy with interferon-α has been
associated with the development of antithyroid microsomal antibodies in 20% of
patients and some have transient hypothyroidism, hyperthyroidism, or both.
Patients who have antithyroid antibodies before treatment are at higher risk for
thyroid dysfunction during treatment. Interleukin-2 has been associated with
transient painless thyroiditis in 20% of patients. Interferon-β and -γ have not
been reported to cause thyroid dysfunction. |
Growth Hormones - Somatrem - Somatropin | Excessive use of thyroid hormones with
growth hormones may accelerate epiphyseal closure. However, untreated
hypothyroidism may interfere with growth response to growth hormone. |
| Ketamine | Concurrent use may produce marked
hypertension and tachycardia; cautious administration to patients receiving
thyroid hormone therapy is recommended. |
Methylxanthine Bronchodilators - (e.g., Theophylline) | Decreased theophylline clearance may
occur in hypothyroid patients; clearance returns to normal when the euthyroid
state is achieved. |
| Radiographic Agents | Thyroid hormones may reduce the uptake
of 123 I, 131I, and 99mTc. |
| Sympathomimetics | Concurrent use may increase the effects
of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk
of coronary insufficiency when sympathomimetic agents are administered to
patients with coronary artery disease. |
Chloral
Hydrate Diazepam Ethionamide Lovastatin Metoclopramide 6-Mercaptopurine Nitroprusside Para-aminosalicylate
sodium Perphenazine Resorcinol (excessive topical use) Thiazide
Diuretics | These agents have been associated with
thyroid hormone and/or TSH level alterations by various
mechanisms. |
Oral anticoagulants
Levothyroxine increases the response to oral anticoagulant
therapy. Therefore, a decrease in the dose of anticoagulant may be warranted
with correction of the hypothyroid state or when the levothyroxine sodium dose
is increased. Prothrombin time should be closely monitored to permit appropriate
and timely dosage adjustments (see Table 2).
Digitalis glycosides
The therapeutic effects of digitalis glycosides may be reduced by
levothyroxine. Serum digitalis glycoside levels may be decreased when a
hypothyroid patient becomes euthyroid, necessitating an increase in the dose of
digitalis glycosides (see Table 2).
Drug-Food Interactions
Consumption of certain foods may affect levothyroxine absorption
thereby necessitating adjustments in dosing. Soybean flour (infant formula),
cotton seed meal, walnuts, and dietary fiber may bind and decrease the
absorption of levothyroxine sodium from the GI tract.
Drug-Laboratory Test Interactions
Changes in TBG concentration must be considered when interpreting
T4 and T3 values, which
necessitates measurement and evaluation of unbound (free) hormone and/or
determination of the free T4 index (FT4I). Pregnancy, infectious hepatitis, estrogens,
estrogen-containing oral contraceptives, and acute intermittent porphyria
increase TBG concentrations. Decreases in TBG concentrations are observed in
nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, and after
androgen or corticosteroid therapy (see also Table 2). Familial hyper- or
hypo-thyroxine binding globulinemias have been described, with the incidence of
TBG deficiency approximating 1 in 9000.
Carcinogenesis, Mutagenesis, and Impairment of
Fertility
Animal studies have not been performed to evaluate the
carcinogenic potential, mutagenic potential or effects on fertility of
levothyroxine. The synthetic T4 in levothyroxine sodium
is identical to that produced naturally by the human thyroid gland. Although
there has been a reported association between prolonged thyroid hormone therapy
and breast cancer, this has not been confirmed. Patients receiving levothyroxine
sodium for appropriate clinical indications should be titrated to the lowest
effective replacement dose.
PregnancyTeratogenic Effects. Pregnancy Category A
Studies in women taking levothyroxine sodium during pregnancy
have not shown an increased risk of congenital abnormalities. Therefore, the
possibility of fetal harm appears remote. Levothyroxine sodium should not be
discontinued during pregnancy and hypothyroidism diagnosed during pregnancy
should be promptly treated.
Hypothyroidism during pregnancy is associated with a higher rate of
complications, including spontaneous abortion, pre-eclampsia, stillbirth and
premature delivery. Maternal hypothyroidism may have an adverse effect on fetal
and childhood growth and development. During pregnancy, serum T4 levels may decrease and serum TSH levels increase to values
outside the normal range. Since elevations in serum TSH may occur as early as 4
weeks gestation, pregnant women taking levothyroxine sodium should have their
TSH measured during each trimester. An elevated serum TSH level should be
corrected by an increase in the dose of levothyroxine sodium. Since postpartum
TSH levels are similar to preconception values, the levothyroxine sodium dosage
should return to the pre-pregnancy dose immediately after delivery. A serum TSH
level should be obtained 6 to 8 weeks postpartum.
Thyroid hormones cross the placental barrier to some extent as evidenced by
levels in cord blood of athyreotic fetuses being approximately one-third
maternal levels. Transfer of thyroid hormone from the mother to the fetus,
however, may not be adequate to prevent in utero
hypothyroidism.
Nursing Mothers
Although thyroid hormones are excreted only minimally in human
milk, caution should be exercised when levothyroxine sodium is administered to a
nursing woman. However, adequate replacement doses of levothyroxine are
generally needed to maintain normal lactation.
Pediatric UseGeneral
The goal of treatment in pediatric patients with hypothyroidism
is to achieve and maintain normal intellectual and physical growth and
development.
The initial dose of levothyroxine varies with age and body weight (see DOSAGE AND ADMINISTRATION: Table
3). Dosing adjustments are based on an assessment of the individual
patient’s clinical and laboratory parameters (see PRECAUTIONS:
Laboratory Tests).
In children in whom a diagnosis of permanent hypothyroidism has not been
established, it is recommended that levothyroxine administration be discontinued
for a 30-day trial period, but only after the child is at least 3 years of age.
Serum T4 and TSH levels should then be obtained. If the
T4 is low and the TSH high, the diagnosis of permanent
hypothyroidism is established, and levothyroxine therapy should be reinstituted.
If the T4 and TSH levels are normal, euthyroidism may be
assumed and, therefore, the hypothyroidism can be considered to have been
transient. In this instance, however, the physician should carefully monitor the
child and repeat the thyroid function tests if any signs or symptoms of
hypothyroidism develop. In this setting, the clinician should have a high index
of suspicion of relapse. If the results of the levothyroxine withdrawal test are
inconclusive, careful follow-up and subsequent testing will be necessary.
Since some more severely affected children may become clinically hypothyroid
when treatment is discontinued for 30 days, an alternate approach is to reduce
the replacement dose of levothyroxine by half during the 30-day trial period.
If, after 30 days, the serum TSH is elevated above 20 mU/L, the diagnosis of
permanent hypothyroidism is confirmed, and full replacement therapy should be
resumed. However, if the serum TSH has not risen to greater than 20 mU/L,
levothyroxine treatment should be discontinued for another 30-day trial period
followed by repeat serum T4 and TSH testing.
The presence of concomitant medical conditions should be considered in
certain clinical circumstances and, if present, appropriately treated (see PRECAUTIONS).
Congenital Hypothyroidism
(see PRECAUTIONS:
Laboratory Tests and DOSAGE AND
ADMINISTRATION)
Rapid restoration of normal serum T4 concentrations is
essential for preventing the adverse effects of congenital hypothyroidism on
intellectual development as well as on overall physical growth and maturation.
Therefore, levothyroxine sodium therapy should be initiated immediately upon
diagnosis and is generally continued for life.
During the first 2 weeks of levothyroxine sodium therapy, infants should be
closely monitored for cardiac overload, arrhythmias, and aspiration from avid
suckling.
The patient should be monitored closely to avoid undertreatment or
overtreatment. Undertreatment may have deleterious effects on intellectual
development and linear growth. Overtreatment has been associated with
craniosynostosis in infants, and may adversely affect the tempo of brain
maturation and accelerate the bone age with resultant premature closure of the
epiphyses and compromised adult stature.
Acquired Hypothyroidism in Pediatric Patients
The patient should be monitored closely to avoid undertreatment
and overtreatment. Undertreatment may result in poor school performance due to
impaired concentration and slowed mentation and in reduced adult height.
Overtreatment may accelerate the bone age and result in premature epiphyseal
closure and compromised adult stature.
Treated children may manifest a period of catch-up growth, which may be
adequate in some cases to normalize adult height. In children with severe or
prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult
height.
Geriatric Use
Because of the increased prevalence of cardiovascular disease
among the elderly, levothyroxine therapy should not be initiated at the full
replacement dose (see WARNINGS, PRECAUTIONS,
and DOSAGE
AND ADMINISTRATION).